Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 17, Issue 6, Pages 917-924Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/13543784.17.6.917
Keywords
diffusion; hypoxia; ischemia; oxygen; respiratory; shock; trans-sodium crocetinate; water structure
Categories
Ask authors/readers for more resources
Background: Trans-sodium crocetinate (TSC) is a novel compound that offers promise as a treatment for conditions caused by hypoxia or ischemia. TSC was originally developed at the University of Virginia for hemorrhagic shock, as part of the battlefield casualty program sponsored by the Us Office of Naval Research. Animal toxicology studies have demonstrated that high levels of TSC are well-tolerated, and a Phase I clinical study has shown that TSC is also safe in humans. Objective: The drug acts via a mechanism that has not been previously exploited in a pharmaceutical. TSC increases the rate of oxygen diffusion between the erythrocytes and the tissues by altering the 'structure' of water in blood plasma. it does this by causing additional hydrogen bonds to form among the water molecules. Conclusion: Further development of TSC for hemorrhagic shock and other hypoxic/ischemic conditions is being done by Diffusion Pharmaceuticals LLC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available